Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
53.82
+1.12 (2.13%)
Nov 21, 2024, 11:24 AM EST - Market open

Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

The company’s pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests.

It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University.

Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation
Exact Sciences logo
Country United States
Founded 1995
Industry Diagnostics & Research
Sector Healthcare
Employees 6,600
CEO Kevin Conroy

Contact Details

Address:
5505 Endeavor Lane
Madison, Wisconsin 53719
United States
Phone 608 284 5700
Website exactsciences.com

Stock Details

Ticker Symbol EXAS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001124140
CUSIP Number 30063P105
ISIN Number US30063P1057
Employer ID 20-4782291
SIC Code 8071

Key Executives

Name Position
Jake Orville MBA Executive Vice President and GM of Screening
Brian Baranick Executive Vice President and General Manager of Precision Oncology
Aaron Bloomer Executive Vice President of Finance
Dr. Jorge A. Garces Ph.D. Chief Science Officer
Nassar Nizami Chief Information Officer
Megan Jones Associate Manager of Investor Relations
Tim Caprez Chief Compliance Counsel and Vice President
James Herriott Senior Vice President, General Counsel and Secretary
Sarah Condella Executive Vice President of Human Resources
Graham P. Lidgard Ph.D. Emeritus Chief Science Officer

Latest SEC Filings

Date Type Title
Nov 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 5, 2024 10-Q Quarterly Report
Nov 5, 2024 8-K Current Report
Oct 8, 2024 144 Filing
Oct 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 18, 2024 144 Filing
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans